Abstract: The present invention relates to a method of determining if a patient is likely to respond to a treatment with a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds. The present invention further relates to a method of identifying a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds for personalized medicine. The present invention also relates to a method of treatment of cancer in a patient. The present invention also relates to a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds for use in a method of treatment of cancer in a patient.

Abstract: The present invention relates to a set of genes for use in a method of predicting the likelihood of a breast cancer patient's survival or of predicting the likelihood of a recurrence and/or aggressiveness of a breast cancer in a breast cancer patient. The present invention also relates to a method for predicting the likelihood of a breast cancer patient's survival or the likelihood of the recurrence or aggressiveness of a breast cancer in a breast cancer patient, as well as to a kit for use in such method.

Abstract: The present invention relates to a set of genes for use in a method of predicting the likelihood of a breast cancer patient's survival or of predicting the likelihood of a recurrence and/or aggressiveness of a breast cancer in a breast cancer patient. The present invention also relates to a method for predicting the likelihood of a breast cancer patient's survival or the likelihood of the recurrence or aggressiveness of a breast cancer in a breast cancer patient, as well as to a kit for use in such method.

Abstract: The present invention relates to a method of determining if a patient is likely to respond to a treatment with a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds. The present invention further relates to a method of identifying a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds for personalized medicine. The present invention also relates to a method of treatment of cancer in a patient. The present invention also relates to a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds for use in a method of treatment of cancer in a patient.

Abstract: The present invention relates to a method of treatment of cancer, said method comprising administering an effective dose of a protein kinase inhibitor to a patient in need thereof having said cancer. The present invention also relates to a method of post-transcriptional control of cancer-related genes comprising administering an effective amount of a protein kinase inhibitor to a subject in need thereof. The present invention further relates to a method of identifying a protein kinase inhibitor for normalizing post-transcriptional regulation as precision cancer therapy.

Abstract: The present invention relates to a method of determining if a patient is likely to respond to a treatment with a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds. The present invention further relates to a method of identifying a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds for personalized medicine. The present invention also relates to a method of treatment of cancer in a patient. The present invention also relates to a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds for use in a method of treatment of cancer in a patient.

Abstract: The present invention relates to a method of treatment of cancer, said method comprising administering an effective dose of a protein kinase inhibitor to a patient in need thereof having said cancer. The present invention also relates to a method of post-transcriptional control of cancer-related genes comprising administering an effective amount of a protein kinase inhibitor to a subject in need thereof.

Abstract: The present invention relates to a set of genes for use in a method of predicting the likelihood of a breast cancer patient's survival or of predicting the likelihood of a recurrence and/or aggressiveness of a breast cancer in a breast cancer patient. The present invention also relates to a method for predicting the likelihood of a breast cancer patient's survival or the likelihood of the recurrence or aggressiveness of a breast cancer in a breast cancer patient, as well as to a kit for use in such method.

Abstract: The present invention relates to fluorescent proteins, in particular green fluorescent proteins (GFPs), with increased activity in cells, and thus increased signal strength. A further aspect of the present invention relates to the use of peptides for increasing the expression and/or stability of a protein in a cell.

Abstract: The present invention describes the use of hybrid short 3? untranslated (3?UTR) regions which are composed of two regions, one region from an 3? untranslated region of a stable eukaryotic mRNA, and another region from the downstream end of an 3? untranslated region of another eukaryotic mRNA that contains a polyadenylation (polyA) signal. The use of such hybrid regions allows for an efficient protein expression when used in conjunction with circular or linear expression DNA molecules. The present invention provides a recombinant DNA that is composed of a promoter, a protein coding region, and the hybrid 3?UTR in a continuous and directional orientation. The efficient expression systems of the invention are suitable for the economical and efficient production of therapeutic proteins and for use with both transient and stable expression systems.

Abstract: The present invention relates to fluorescent proteins, in particular green fluorescent proteins (GFPs), with increased activity in cells, and thus increased signal strength. A further aspect of the present invention relates to the use of peptides for increasing the expression and/or stability of a protein in a cell.

Abstract: The present invention relates to expression vector comprising (a) a promoter region comprising a non-inducible constitutively active ribosomal protein gene promoter, (b) an operably linked reporter or gene sequence, and (c) a 3? untranslated region (3? UTR), which are suitable means for an selective assessment of post-transcriptional regulation, post-transcriptional control elements and factors as well as for identifying compounds that effect post-transcription. The present invention furthermore relates to arrays, expression vector libraries and cell lines containing the expression vector(s). The present invention furthermore relates to a method and kit for identifying compounds that affect post-transcriptional regulation of reporter(s) or gene(s), that utilize the expression vector(s).

Abstract: The present invention relates to fluorescent proteins, in particular green fluorescent proteins (GFPs), with increased activity in cells, and thus increased signal strength. A further aspect of the present invention relates to the use of peptides for increasing the expression and/or stability of a protein in a cell.

Abstract: The present invention relates to a (first) method for producing inducible and/or repressible expression active linear RNA interference constructs comprising a PCR amplification of a source polynucleotide comprising the inhibitory RNA coding sequence of interest or comprising a PCR amplification of a DNA source comprising a promoter using a reverse primer comprising the inhibitory RNA coding sequence of interest. The present invention furthermore relates to a (second) method for producing inducible and/or repressible expression active linear gene constructs comprising a PCR amplification of a source expression polynucleotide comprising a promoter sequence and the DNA sequence of interest or comprising a PCR amplification using the DNA sequence as a template.

Abstract: The present invention relates to fluorescent proteins, in particular green fluorescent proteins (GFPs), with increased activity in cells, and thus increased signal strength. A further aspect of the present invention relates to the use of peptides for increasing the expression and/or stability of a protein in a cell.

Abstract: The present invention relates to expression vector comprising (a) a promoter region comprising a non-inducible constitutively active ribosomal protein gene promoter, (b) an operably linked reporter or gene sequence, and (c) a 3? untranslated region (3? UTR), which are suitable means for an selective assessment of post-transcriptional regulation, post-transcriptional control elements and factors as well as for identifying compounds that effect post-transcription. The present invention furthermore relates to arrays, expression vector libraries and cell lines containing the expression vector(s). The present invention furthermore relates to a method and kit for identifying compounds that affect post-transcriptional regulation of reporter(s) or gene(s), that utilize the expression vector(s).

Abstract: The present invention relates to a (first) method for producing inducible and/or repressible expression active linear RNA interference constructs comprising a PCR amplification of a source polynucleotide comprising the inhibitory RNA coding sequence of interest or comprising a PCR amplification of a DNA source comprising a promoter using a reverse primer comprising the inhibitory RNA coding sequence of interest. The present invention furthermore relates to a (second) method for producing inducible and/or repressible expression active linear gene constructs comprising a PCR amplification of a source expression polynucleotide comprising a promoter sequence and the DNA sequence of interest or comprising a PCR amplification using the DNA sequence as a template.

Abstract: The present invention describes the use of hybrid short 3? untranslated (3?UTR) regions which are composed of two regions, one region from an 3? untranslated region of a stable eukaryotic mRNA, and another region from the downstream end of an 3? untranslated region of another eukaryotic mRNA that contains a polyadenylation (polyA) signal. The use of such hybrid regions allows for an efficient protein expression when used in conjunction with circular or linear expression DNA molecules. The present invention provides a recombinant DNA that is composed of a promoter, a protein coding region, and the hybrid 3?UTR in a continuous and directional orientation. The efficient expression systems of the invention are suitable for the economical and efficient production of therapeutic proteins and for use with both transient and stable expression systems.

Abstract: The present invention relates to a gene discovery system and gene expression systems specific for genes encoding ARE-containing mRNAs. In one aspect, the present invention relates to computational methods of selecting coding sequences of ARE-genes from databases using a one or more ARE search sequences. The ARE search sequences are from 10 to 80 nucleotides in length and comprise a sequence which is encompassed by one of the following two sequences: (a) WU/T(AU/TU/TU/TA)TWWW, SEQ ID NO. 1, wherein none or one of the nucleotides outside of the parenthesis is replaced by a different nucleotide, and wherein W represents A, U, or T; and (b) U/T(AU/TU/T/U/T)n, SEQ ID NO. 2 wherein n indicates that the search sequence comprises from 3 to 12 of the tetrameric sequences contained within the parenthesis. The method comprises extracting from the databases, those nucleic acids whose protein coding sequences are upstream and contiguous with a 3? untranslated region (UTR) that comprises one of the ARE search sequences.

Abstract: The present invention relates to a gene discovery system and gene expression systems specific for genes encoding ARE-containing mRNAs. In one aspect, the present invention relates to computational methods of selecting coding sequences of ARE-genes from databases using aone or more ARE search sequences. The ARE search sequences are from 10 to 80 nucleotides in length and comprise a sequence which is encompassed by one of the following two sequences: (a) WU/T(AU/TU/TU/TA)TWWW, SEQ ID NO. 1, wherein none or one of the nucleotides outside of the parenthesis is replaced by a different nucleotide, and wherein W represents A, U. or T; and (b) U/T(AU/TU/T/U/T)n, SEQ ID NO. 2, wherein n indicates that the search sequence comprises from 3 to 12 of the tetrameric sequences contained within the parenthesis. The method comprises extracting from the databases, those nucleic acids whose protein coding sequences are upstream and contiguous with a 3?untranslated region (UTR) that comprises one of the ARE search sequences.